December 15th, 2015

Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process)

[Business Wire] – Today Biogen Idec and AbbVie announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA™ , do Read more on this. Biogen Idec Inc. (BIIB), . . . → Read More: Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process) Similar Articles: Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Donald Johns Joins Biogen Idec to Lead ALS Innovation Hub Biogen Idec Inc (NASDAQ:BIIB) | ISIS Pharmaceuticals’ and Biogen idec’s innovative collaboration voted breakthrough alliance of 2014 Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Idec to Present New Two-Year Data from the PLEGRIDY™ (Peginterferon Beta-1a) Phase 3 ADVANCE Study at AAN Annual Meeting
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.